Lidwine W. Tick

Hoofddorp, NH, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 58 publications

Treatment Patterns, Outcomes and Survival Trends in T-Cell Prolymphocytic Leukemia: A Nationwide Population-Based Study in the Netherlands.

Treatment Patterns, Outcomes and Survival Trends in T-Cell Prolymphocytic Leukemia: A Nationwide Population-Based Study in the Netherlands.

Journal: European journal of haematology

Published: April 27, 2026

Flow Cytometry-Based Measurable Residual Disease Assessment in Patients With Acute Myeloid Leukemia Receiving Non-Intensive Chemotherapy.

Flow Cytometry-Based Measurable Residual Disease Assessment in Patients With Acute Myeloid Leukemia Receiving Non-Intensive Chemotherapy.

Journal: American journal of hematology

Published: January 29, 2026

Hypomethylating agents with venetoclax for newly diagnosed acute myeloid leukemia in patients 65 and older in The Netherlands - A nationwide study of drug usage and treatment outcomes.

Hypomethylating agents with venetoclax for newly diagnosed acute myeloid leukemia in patients 65 and older in The Netherlands - A nationwide study of drug usage and treatment outcomes.

Journal: European journal of cancer (Oxford, England : 1990)

Published: December 31, 2025

Pharmacological boosting of azacitidine/venetoclax in acute myeloid leukemia.

Pharmacological boosting of azacitidine/venetoclax in acute myeloid leukemia.

Journal: Blood neoplasia

Published: December 02, 2025

Venetoclax plus hypomethylating agents as a bridge to transplant or donor lymphocyte infusion in relapsed/ refractory acute myeloid leukemia.

Venetoclax plus hypomethylating agents as a bridge to transplant or donor lymphocyte infusion in relapsed/ refractory acute myeloid leukemia.

Journal: Haematologica

Published: May 08, 2025

Risk Stratification in Older Intensively Treated Patients With AML.

Risk Stratification in Older Intensively Treated Patients With AML.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: September 04, 2024

Midostaurin added to 10-day decitabine, for patients unfit for intensive chemotherapy with AML and higher risk MDS, irrespective of FLT3 mutational status, does not improve outcome.

Midostaurin added to 10-day decitabine, for patients unfit for intensive chemotherapy with AML and higher risk MDS, irrespective of FLT3 mutational status, does not improve outcome.

Journal: Annals of hematology

Published: July 23, 2024

Impact of comorbidity on health-related quality of life in newly diagnosed patients with lymphoma or multiple myeloma: results from the PROFILES-registry.

Impact of comorbidity on health-related quality of life in newly diagnosed patients with lymphoma or multiple myeloma: results from the PROFILES-registry.

Journal: Annals of hematology

Published: July 10, 2024

Patency and reflux in relation to postthrombotic syndrome: a subanalysis of the Ultrasound-Accelerated Catheter-Directed Thrombolysis Versus Anticoagulation for the Prevention of Post-Thrombotic Syndrome trial.

Patency and reflux in relation to postthrombotic syndrome: a subanalysis of the Ultrasound-Accelerated Catheter-Directed Thrombolysis Versus Anticoagulation for the Prevention of Post-Thrombotic Syndrome trial.

Journal: Journal of thrombosis and haemostasis : JTH

Published: June 05, 2024

Associations of various medical nutrition therapy strategies with body composition, and physical and clinical outcomes in acute myeloid leukemia patients undergoing intensive remission-induction treatment: A multicenter prospective correlational study.

Associations of various medical nutrition therapy strategies with body composition, and physical and clinical outcomes in acute myeloid leukemia patients undergoing intensive remission-induction treatment: A multicenter prospective correlational study.

Journal: Clinical nutrition ESPEN

Published: June 05, 2024

HOVON 104, long-term follow-up of bortezomib-dexamethasone induction therapy followed by autologous stem cell transplantation in newly diagnosed AL amyloidosis patients.

HOVON 104, long-term follow-up of bortezomib-dexamethasone induction therapy followed by autologous stem cell transplantation in newly diagnosed AL amyloidosis patients.

Journal: EJHaem

Published: April 15, 2024

Changes in nutritional status and associations with physical and clinical outcomes in acute myeloid leukemia patients during intensive chemotherapy.

Changes in nutritional status and associations with physical and clinical outcomes in acute myeloid leukemia patients during intensive chemotherapy.

Journal: European journal of clinical nutrition

Published: December 21, 2023

Showing 1-12 of 58

Last Updated: 09/26/2026